Download MendeleyDiscovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
Bencsik, J.R., Xiao, D., Blake, J.F., Kallan, N.C., Mitchell, I.S., Spencer, K.L., Xu, R., Gloor, S.L., Martinson, M., Risom, T., Woessner, R.D., Dizon, F., Wu, W.I., Vigers, G.P., Brandhuber, B.J., Skelton, N.J., Prior, W.W., Murray, L.J.(2010) Bioorg Med Chem Lett 20: 7037-7041
- PubMed: 20971641
- DOI: https://doi.org/10.1016/j.bmcl.2010.09.112
- Primary Citation of Related Structures:
3OW3, 3OW4 - PubMed Abstract:
Herein we report the discovery and synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines (2 and 3) as potent pan Akt inhibitors. Utilizing previous SAR and analysis of the amino acid sequences in the binding site we have designed inhibitors displaying increased PKA and general kinase selectivity with improved tolerability compared to the progenitor pyrrolopyrimidine (1). A representative dihydrothieno compound (34) was advanced into a PC3-NCI prostate mouse tumor model in which it demonstrated a dose-dependent reduction in tumor growth and stasis when dosed orally daily at 200 mg/kg.
Organizational Affiliation:
Array BioPharma Inc., Boulder, CO 80301, USA. jbencsik@arraybiopharma.com
